{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T08:53:36Z","timestamp":1776502416246,"version":"3.51.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Psoriasis vulgaris is a chronic skin disease which is related to cardiovascular and metabolic diseases. In the pathogenesis of these diseases, adipokines, including retinol binding protein-4 (RBP-4), play crucial roles. Studies have also shown that RBP-4 might be a meaningful factor in psoriasis however, relying on the analysis of a single study have some drawbacks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the association between RBP-4 and psoriasis vulgaris more comprehensively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Six databases were searched to obtain relevant publications. The selection of the included studies was based on a criteria. The standardized mean difference (SMD) was used for analysis. A value of <jats:italic>p<\/jats:italic> &amp;lt; 0.05 was defined as significance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seven studies were included, with 271 cases and 235 controls. In the comparison between patients and controls, the merged data suggested that levels of RBP-4 were significantly higher in patients (SMD\u2009=\u20090.61, 95%CI: 0.14, 1.07, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05). In five studies containing the data of RBP-4 levels before and after treatment, no significance was found, either for RBP-4 levels in the after-treatment group and control group in these five studies (<jats:italic>p<\/jats:italic>\u2009&amp;gt;\u20090.05). Subgroup analysis was conducted based on the therapy method. Patients with systematic treatment showed a significant decrease of BRP-4 level after the treatment (SMD\u2009=\u2009\u22120.64, 95%CI: \u22121.26, \u22120.03, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>For patients with psoriasis vulgaris, RBP-4 levels are elevated, and systematic treatment can lower these levels. RBP-4 might act as a key indicator for the diagnosis, efficacy assessment, and comorbidity monitoring of the patients. Further studies with well-designed protocols and enlarged populations are still needed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1208969","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T13:18:56Z","timestamp":1693401536000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Association between retinol binding protein-4 and psoriasis vulgaris: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"10","author":[{"given":"Guangcheng","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuli","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.3390\/ijms22062979","article-title":"Psoriasis: pathogenesis, comorbidities, and therapy updated","volume":"22","author":"Kanda","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/ijd.14032","article-title":"Stress and psoriasis","volume":"57","author":"Rousset","year":"2018","journal-title":"Int J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1161\/CIRCULATIONAHA.116.026859","article-title":"Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study","volume":"136","author":"Lerman","year":"2017","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/1346-8138.15840","article-title":"Psoriasis: Comorbidities","volume":"48","author":"Yamazaki","year":"2021","journal-title":"J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s12325-020-01346-6","article-title":"Psoriasis and cardiovascular risk: a comprehensive review","volume":"37","author":"Masson","year":"2020","journal-title":"Adv Ther"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1080\/14712598.2022.2093106","article-title":"Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome","volume":"22","author":"Trovato","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2174\/1871530319666191008170409","article-title":"The association of metabolic syndrome and psoriasis: a systematic review and meta-analysis of observational study","volume":"20","author":"Choudhary","year":"2020","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.3390\/molecules25215218","article-title":"An overview of the role of adipokines in cardiometabolic diseases","volume":"25","author":"Farkhondeh","year":"2020","journal-title":"Molecules"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.tips.2015.04.014","article-title":"Adipokines in health and disease","volume":"36","author":"Fasshauer","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"111312","DOI":"10.1016\/j.mce.2021.111312","article-title":"Retinol-binding protein 4 in obesity and metabolic dysfunctions","volume":"531","author":"Nono Nankam","year":"2021","journal-title":"Mol Cell Endocrinol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1093\/advances\/nmz131","article-title":"Retinol, retinoic acid, and retinol-binding protein 4 are differentially associated with cardiovascular disease, type 2 diabetes, and obesity: an overview of human studies","volume":"11","author":"Olsen","year":"2020","journal-title":"Adv Nutr"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.dsx.2021.03.019","article-title":"Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: a comprehensive systematic review and meta-analysis","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1080\/1354750X.2022.2046855","article-title":"Association of CTLA-4 gene polymorphisms and alopecia areata: a systematic review and meta-analysis","volume":"27","author":"Zhou","year":"2022","journal-title":"Biomarkers"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000351769","article-title":"The effect of acitretin treatment on insulin resistance, retinol-binding protein-4, leptin, and adiponectin in psoriasis vulgaris: a noncontrolled study","volume":"227","author":"Karadag","year":"2013","journal-title":"Dermatology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00403-012-1306-5","article-title":"Circulating levels of lipocalin-2 and retinol-binding protein-4 are increased in psoriatic patients and correlated with baseline PASI","volume":"305","author":"Romani","year":"2013","journal-title":"Arch Dermatol Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1684\/ejd.2014.2490","article-title":"Changes of serum lipocalin-2 and retinol binding protein-4 levels in patients with psoriasis and Beh\u00e7et's disease","volume":"25","author":"Gul","year":"2015","journal-title":"Eur J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7860\/JCDR\/2016\/21724.8369","article-title":"Retinol binding protein 4 in non obese psoriatic cases","volume":"10","author":"Bakry","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3109\/09546634.2015.1079300","article-title":"The effect of topical treatment and psoriasis severity on serum retinol-binding protein-4 levels","volume":"27","author":"Baran","year":"2016","journal-title":"J Dermatol Treat"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5021\/ad.2016.28.1.74","article-title":"Association of Adipokines, insulin resistance, hypertension and Dyslipidemia in patients with psoriasis vulgaris","volume":"28","author":"Coban","year":"2016","journal-title":"Ann Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3969\/j.issn.1674-9081.2019.03.010","article-title":"Effects of the receptor-IgG fc fusion protein of recombinant type II human tumor necrosis factor-\u03b1 on the levels of serum adipokines in psoriatic patients:a prospective non-randomized controlled trial","volume":"10","author":"Qiao","year":"2019","journal-title":"Med J Peking Union Med Coll Hosp"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1007\/s00246-022-02869-1","article-title":"Psoriasis and cardiovascular risk in children: the usefulness of carotid intima-media thickness","volume":"43","author":"Fabi","year":"2022","journal-title":"Pediatr Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3390\/pharmaceutics14030654","article-title":"Impact of pharmacokinetic and pharmacodynamic properties of monoclonal antibodies in the Management of Psoriasis","volume":"14","author":"Rodr\u00edguez-Fern\u00e1ndez","year":"2022","journal-title":"Pharmaceutics"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e15506","DOI":"10.1111\/dth.15506","article-title":"Anti-IL23 for nail psoriasis in real life: results of efficacy and safety during a 52-week period","volume":"35","author":"Trovato","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/jre.13078","article-title":"Impact of periodontitis on gingival crevicular fluid miRNAs profiles associated with cardiovascular disease risk","volume":"58","author":"Isola","year":"2023","journal-title":"J Periodontal Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/odi.12180","article-title":"Differential expression of transglutaminase genes in patients with chronic periodontitis","volume":"20","author":"Curr\u00f2","year":"2014","journal-title":"Oral Dis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/odi.13960","article-title":"Analysis of the response to two pharmacological protocols in patients with oral lichen planus: a randomized clinical trial","volume":"29","author":"Polizzi","year":"2023","journal-title":"Oral Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/jdv.13005","article-title":"Anti-TNF-\u03b1 therapy reduces retinol-binding protein 4 serum levels in non-diabetic patients with psoriasis: a 6-month prospective study","volume":"30","author":"Pina","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1600-0625.2011.01402.x","article-title":"Leptin, adiponectin, visfatin and retinol-binding protein-4\u2014mediators of comorbidities in patients with psoriasis?","volume":"21","author":"Gerdes","year":"2012","journal-title":"Exp Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.36849\/JDD.2020.5366","article-title":"Geographic variations in biologic therapy and disease characteristics: a pilot-study in the Corrona psoriasis registry","volume":"19","author":"Enos","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23736\/S2784-8671.21.07132-2","article-title":"Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis","volume":"157","author":"Gisondi","year":"2022","journal-title":"Ital J Dermatol Venerol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13071-022-05242-6","article-title":"The distribution of Dermacentor reticulatus in the Czech Republic re-assessed: citizen science approach to understanding the current distribution of the babesia canis vector","volume":"15","author":"Dan\u011bk","year":"2022","journal-title":"Parasit Vectors"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12917-022-03249-w","article-title":"Mycobacterium bovis and M. caprae in Bulgaria: insight into transmission and phylogeography gained through whole-genome sequencing","volume":"18","author":"Valcheva","year":"2022","journal-title":"BMC Vet Res"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1208969\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T13:19:03Z","timestamp":1693401543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1208969\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,30]]},"references-count":37,"alternative-id":["10.3389\/fmed.2023.1208969"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1208969","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,30]]},"article-number":"1208969"}}